Program
pomalidomide
Also written as “Pomalidomide”, “Pomalidomide 4 MG Oral Capsule” and “Xetrane® (Pomalidomide) 4 mg Hard Capsule”.
Its studies are mostly in Multiple Myeloma · Primary Myelofibrosis · Brain Neoplasms · Scleroderma, Systemic · Hematologic Neoplasms, led by 8 companies.
Drug pagePomalidomide: every studyMany companies study it; this page follows only the 37 they lead. All 160 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 251 open or running | phase 3since Jul 15, 2010 | Nov 7, 2003 | Jan 10, 2027phase 3 · NCT05519085 |
| Oncotherapeuticsits history only | 40 open or running | phase 2since Feb 20, 2012 | Feb 20, 2012 | none ahead |
| Amgenits history only | 20 open or running | phase 2since Nov 22, 2019 | Oct 18, 2016 | none ahead |
| Simcere Pharmaceutical Groupits history only | 20 open or running | phase 3since Sep 24, 2016 | Sep 24, 2016 | none ahead |
| Criteriumits history only | 10 open or running | phase 2since Oct 19, 2011 | Oct 19, 2011 | none ahead |
| Knight Therapeutics (USA)its history only | 10 open or running | phase 1since Jul 3, 2026 | Jul 3, 2026 | none ahead |
| Megalabsits history only | 11 open or running | phase 1since Sep 15, 2023 | Sep 15, 2023 | none ahead |
| Takedaits history only | 10 open or running | phase 4since Dec 20, 2021 | Dec 20, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bristol-Myers Squibb only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 10 studies since Nov 7, 2003.
- Jan 27, 2012Phase 1 study in Anemia, Sickle CellNCT01522547 · 12 enrolled · United States
- Mar 19, 2012Phase 2 study in Scleroderma, SystemicNCT01559129 · 23 enrolled · United States, Australia, France and more
- Mar 29, 2012Phase 1 study in Multiple MyelomaNCT01568294 · 12 enrolled · Japan
- Oct 12, 2012Phase 1 study in Pharmacology, ClinicalNCT01707407 · 32 enrolled · United States
- Oct 22, 2012Phase 3 study in Multiple MyelomaNCT01712789 · 682 enrolled · Austria, Belgium, Denmark and more
- Nov 23, 2012Phase 3 study in Multiple MyelomaNCT01734928 · 559 enrolled · United States, Austria, Canada and more
- Apr 17, 2013Phase 1 study in Liver DiseasesNCT01835561 · 32 enrolled · United States
- Sep 17, 2013Phase 2 study in Multiple MyelomaNCT01946477 · 186 enrolled · United States, Canada, Japan and more
- Nov 12, 2013Phase 1 study in Clinical Pharmacology, Healthy Volunteer StudyNCT01986894 · 72 enrolled · United States
- Dec 10, 20132 phase 2 studies in Multiple MyelomaNCT02011113, NCT02045017
- Jun 18, 2014Phase 1 study in Healthy VolunteersNCT02168205 · 55 enrolled · United States
- Aug 18, 2017Phase 2 study in Central Nervous System NeoplasmsNCT03257631 · 53 enrolled · United States, France, Italy and more
- Aug 16, 2018Phase 3 study in Multiple MyelomaNCT03651128 · 386 enrolled · United States, Belgium, Canada and more
- Aug 25, 2022Phase 3 study in RecurrenceNCT05519085 · 810 planned · United States, Argentina, Australia and more
Ahead
- Jan 10, 2027Primary completion: phase 3 study in RecurrenceNCT05519085
TargetBeta
“CRL4(CRBN) E3 ubiquitin ligase inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lenalidomiderule | Bristol-Myers Squibb | phase 4 | 109 |
Studies
All 25 Bristol-Myers Squibb leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05519085Recurrence · United States, Argentina, Australia and more | 3 | Recruiting | Jan 10, 2027 | 810 |
| NCT03651128Multiple Myeloma · United States, Belgium, Canada and more | 3 | Completed | Apr 13, 2026 | 386 |
| NCT03257631Central Nervous System Neoplasms · United States, France, Italy and more | 2 | Completed | Sep 14, 2023 | 53 |
| NCT02168205Healthy Volunteers · United States | 1 | Completed | Sep 19, 2014 | 55 |
| NCT02045017Multiple Myeloma · Austria, France, Germany and more | 2 | Completed | Jan 27, 2017 | 81 |
| NCT02011113Multiple Myeloma · Japan | 2 | Completed | Sep 2014 | 36 |
| NCT01986894Clinical Pharmacology, Healthy Volunteer Study · United States | 1 | Completed | Dec 2, 2013 | 72 |
| NCT01946477Multiple Myeloma · United States, Canada, Japan and more | 2 | Completed | Apr 30, 2025 | 186 |
| NCT01835561Liver Diseases · United States | 1 | Completed | Aug 16, 2014 | 32 |
| NCT01734928Multiple Myeloma · United States, Austria, Canada and more | 3 | Completed | May 9, 2022 | 559 |
| NCT01712789Multiple Myeloma · Austria, Belgium, Denmark and more | 3 | Completed | Dec 11, 2019 | 682 |
| NCT01707407Pharmacology, Clinical · United States | 1 | Completed | Nov 1, 2012 | 32 |
| NCT01568294Multiple Myeloma · Japan | 1 | Completed | Jul 8, 2015 | 12 |
| NCT01559129Scleroderma, Systemic · United States, Australia, France and more | 2 | Terminated | Nov 3, 2016 | 23 |
| NCT01522547Anemia, Sickle Cell · United States | 1 | Completed | Oct 1, 2012 | 12 |
| NCT01497093Multiple Myeloma · United States | 1 | Completed | Jul 23, 2019 | 34 |
| NCT01474330Healthy · United States | 1 | Completed | Oct 1, 2011 | 33 |
| NCT01324947Multiple Myeloma · Australia, Belgium, Canada and more | 3 | Completed | Jul 31, 2014 | 74 |
| NCT01311687Multiple Myeloma · United States, Australia, Belgium and more | 3 | Completed | Mar 1, 2013 | 455 |
| NCT01178281Primary Myelofibrosis · United States, Australia, Austria and more | 3 | Completed | Jan 1, 2013 | 267 |
| NCT00833833Multiple Myeloma · United States, Canada | 2 | Completed | Apr 2011 | 259 |
| NCT00717522Sarcoma · United States | 2 | Terminated | Jan 1, 2009 | 7 |
| NCT00537511Carcinoma, Small Cell · United States, Canada | 2 | Terminated | Nov 1, 2010 | 22 |
| NCT00463385Primary Myelofibrosis · United States, Austria, Italy and more | 2 | Completed | May 1, 2009 | 88 |
| NCT00072722Prostatic Neoplasms · United States | 2 | Completed | 36 |
How it is read
Names in the registry
- “Pomalidomide”, 41 entries
- “pomalidomide”, 4 entries
- “Pomalidomide 4 MG Oral Capsule”, 2 entries
- “Xetrane® (Pomalidomide) 4 mg Hard Capsule”, 1 entry
- “Imnovid® (Pomalidomide) 4 mg Hard Capsule”, 1 entry
Codes read as this program: CC4047.
Conditions, from the studies’ own filings
- Multiple Myeloma, 35 studies
- Primary Myelofibrosis, 2 studies
- Brain Neoplasms, 1 study
- Scleroderma, Systemic, 1 study
- Hematologic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.